Asking the right questions: developing evidencebased strategies for treating HIV in women and children

Karim, Quarraisha Abdool; Banegura, Anchilla; Cahn, Pedro; Christie, Celia D. C.; Dintruff, Robert; Distel, Manuel; Hankins, Catherine; Hellmann, Nicholas; Katabira, Elly; Lehrman, Sandra; Montaner, Julio; Purdon, Scott; Rooney, James F.; Wood, Robin; Heidari, Shirin
January 2011
BMC Public Health;2011 Supplement 4, Vol. 11 Issue Suppl 4, p388
Academic Journal
In July 2010, the World Health Organization (WHO) issued formal revisions of its guidelines on the use of highly active antiretroviral therapy for HIV. The new guidelines greatly expand eligibility for treatment of adults and children, as well as for pregnant women seeking prophylaxis for vertical HIV transmission. WHO's new recommendations bring the guidelines closer to practices in developed countries, and its shift to earlier treatment alone will increase the number of treatment-eligible people by 50% or more. Scaling up access to HIV treatment is revealing important gaps in our understanding of how best to provide for all those in need. This knowledge gap is especially significant in developing countries, where women and children comprise a majority of those living with HIV infection. Given the magnitude and significance of these populations, the International AIDS Society, through its Industry Liaison Forum, prioritized HIV treatment and prophylaxis of women and children. In March 2010, the International AIDS Society and 15 partners launched a Consensus Statement outlining priority areas in which a relative lack of knowledge impedes delivery of optimal prevention of mother to child transmission (PMTCT) and treatment to women and children. The Consensus Statement, "Asking the Right Questions: Advancing an HIV Research Agenda for Women and Children", makes a special appeal for a more gender-sensitive approach to HIV research at all stages, from conception to design and implementation. It particularly emphasizes research to enhance the understanding of sex-based differences and paediatric needs in treatment uptake and response. In addition to clinical issues, the statement focuses on programmatic research that facilitates access and adherence to antiretroviral regimens. Better coordination of HIV management with sexual and reproductive healthcare delivery is one such approach. We discuss here our knowledge gaps concerning effective, safe PMTCT and treatment for women and children in light of the expansion envisioned by WHO's revised guidelines. The guideline's new goals present an opportunity for advancing the women and children's agenda outlined in the Consensus Statement.


Related Articles

  • Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges? Boullie, A.; Ford, N. // Sexually Transmitted Infections;Dec2007, Vol. 83 Issue 8, p503 

    The article comments on the need for cost-effective interventions to reduce HIV in developing countries. There have been concerns on the promotion of widespread access to antiretroviral therapy in Southern Africa. Data on the effectiveness of the interventions since year 2000 have been compiled....

  • AIDS BRIEF. Alcorn, Keith // CME: Continuing Medical Education;Jun2011, Vol. 29 Issue 6, p262 

    The article discusses research concerning the use of antiretroviral treatment for reducing risk of HIV transmission. The large randomised study involves male-female couples with one HIV-positive partner. The participants from several countries including Botswana, Brazil, and India received...

  • Mainstream print media reporting of HIV increases 2000-2003. Hurley, Michael; Croy, Samantha; Machon, Kirsty // HIV Australia;Dec2003-Feb2004, Vol. 3 Issue 2, p6 

    Focuses on the system of mainstream print media reporting of HIV increases in Australia from 2000 to 2003. Events where mainstream print media reporting of domestic HIV/AIDS is organized; Media reporting of HIV in countries with early epidemics among gay men; Media representations of antiviral...

  • An Attenuated Herpes Simplex Virus Type 1 (HSV1) Encoding the HIV-1 Tat Protein Protects Mice from a Deadly Mucosal HSV1 Challenge. Sicurella, Mariaconcetta; Nicoli, Francesco; Gallerani, Eleonora; Volpi, Ilaria; Berto, Elena; Finessi, Valentina; Destro, Federica; Manservigi, Roberto; Cafaro, Aurelio; Ensoli, Barbara; Caputo, Antonella; Gavioli, Riccardo; Marconi, Peggy C. // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Herpes simplex virus types 1 and 2 (HSV1 and HSV2) are common infectious agents in both industrialized and developing countries. They cause recurrent asymptomatic and/or symptomatic infections, and life-threatening diseases and death in newborns and immunocompromised patients. Current treatment...

  • HIV treatment will boost pre- vention and strengthen health systems,says The world health report 2004.  // Bulletin of the World Health Organization;Jun2004, Vol. 82 Issue 6, p477 

    The article presents information on the World Health Report 2004 , launched by World Health Organization in Geneva on May 11, 2004. The report reveals that by using human immunodeficiency virus treatment programs to holster existing prevention efforts and improve overall health systems in the...


    Background: The high cost of antiretroviral (ARV) drugs has led to the initiation of subsidized HIV treatment programs in developing countries. The care of tuberculosis (TB), a common opportunistic infection, is not built into the subsidized program. Objective: To evaluate the cost burden of...

  • Impact of New Developments in Antiretroviral Treatment on AIDS Prevention and Care in... Colebunders, Robert; Verdonck, Kristien // AIDS Patient Care & STDs;May2000, Vol. 14 Issue 5, p251 

    Discusses how breakthroughs in antiretroviral (ARV) treatment could hasten care and prevention of AIDS in developing countries. Barriers to the introduction of ARV in developing countries; Results of the study conducted on non-breast-feeding population in Thailand; Priority of ARV treatment...

  • What's new for injection drug users with HIV infections? Clarke, S.M.; Mulcahy, F.M. // Sexually Transmitted Infections;Apr2003, Vol. 79 Issue 2, p80 

    Presents results of a literature review of published data from 1999 to 2001 that related to injection drug users (IDU) with HIV infection. Increasing epidemics of HIV infection in IDUs in developing countries; Improving access to care for IDUs; Co-infection with hepatitis C virus;...

  • Lopinavir/Ritonavir: A Review of its Use in the Management of HIV Infection. Cvetkovic, Risto S.; Goa, Karen L. // Drugs;2003, Vol. 63 Issue 8, p769 

    Lopinavir is a novel protease inhibitor (PI) developed from ritonavir. Coadministration with low-dose ritonavir significantly improves the pharmacokinetic properties and hence the activity of lopinavir against HIV-1 protease. Coformulated lopinavir/ritonavir was developed for ease of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics